Clinical trials: Anti-PD-1
Metastatic Non-squamous Non Small Cell Lung Cancer
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
This is an efficacy and safety study of cosibelimab (CK-301) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic non-squamous non-small cell…
- Trial name
- CONTERNO (NCT04786964)
- Testing
- Cosibelimab, Cisplatin, Carboplatin
- Where
- 22 sites in Brazil, Georgia and 6 more
- Volunteers
- 25 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Lymphoma, Lung Cancer
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
The primary objective is to assess the safety and tolerability of JS-001 in subjects with various advanced or recurrent malignancies, including solid tumors and lymphomas, and to evaluate its preliminary efficacy.
- Trial name
- NCT02836834
- Testing
- JS001
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Neoplasms by Site
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or…
- Trial name
- NCT01968109
- Testing
- Relatlimab, Nivolumab, BMS-986213
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 1,482 people
- Sponsor
- Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma
PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
This study aims to establish whether the combination of pembrolizumab (MK-3475) and conventional cisplatin-based chemoradiotherapy is tolerable and results in acceptable levels of acute and late toxicity in patients with stage IV…
- Trial name
- PEACH (NCT02819752)
- Testing
- Pembrolizumab, Radiotherapy, Chemotherapy
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Rectal Neoplasms
Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC
The purpose of this study is to explore whether rectal artery infusion chemotherapy combined with anti-PD1 antibody is an effective neoadjuvant therapy for the microsatellite stable locally advanced rectal cancer.
- Trial name
- RAIC (NCT05307198)
- Testing
- Oxaliplatin, Rectectomy, Capecitabine
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and…
- Trial name
- NCT03767582
- Testing
- Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early Stage Non-Small Cell Lung Cancer
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT03050554
- Testing
- Avelumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Andrew Sharabi
NSCLC Stage IV, Oligometastasis
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment of NSCLC, from back-line to first-line, and…
- Trial name
- NCT05055583
- Testing
- Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment stage, Adjuvant treatment stage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Cancer
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
LVGN7409 is a humanized monoclonal antibody that specifically binds to CD40, and acts as an agonist against CD40. This first in human study of LVGN7409 is designed to establish the maximum tolerated dose (MTD) and/or the…
- Trial name
- NCT04635995
- Testing
- LVGN7409
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Lyvgen Biopharma Holdings Limited
Intrahepatic Cholangiocarcinoma
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma after progression on first line systemic therapy.
- Trial name
- NCT04299581
- Testing
- Camrelizumab, US/CT-guided Percutaneous Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Solid Tumor, Lymphoma
A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in subjects with advanced solid tumors or lymphoma.
- Trial name
- NCT03809767
- Testing
- CS1003 monoclonal antibody
- Where
- 17 sites in China
- Volunteers
- 107 people
- Sponsor
- CStone Pharmaceuticals
Carcinosarcoma of Ovary, Carcinosarcoma of Uterus
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
The purpose of this study is to test the safety of Cabozantinib in combination with Nivolumab and Ipilimumab and see what affects that this combination treatment has on those with recurrent carcinosarcomas.
- Conditions
- Carcinosarcoma of Ovary, Carcinosarcoma of Uterus, Carcinosarcoma of Vagina
- Trial name
- NCT04149275
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e.
- Trial name
- ROCSAN (NCT03651206)
- Testing
- Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
- Where
- 36 sites in France, Italy and 1 more
- Volunteers
- 138 people
- Sponsor
- ARCAGY/ GINECO GROUP
Non Small Cell Lung Cancer
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients…
- Trial name
- NCT05641493
- Testing
- HLX208+HLX10
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Henlius Biotech
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)
To investigate the effects of the combination of two chemotherapies followed by immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in the tumour microenvironment in patients with previously…
- Trial name
- AuspiCiOus (NCT05177133)
- Testing
- Capecitabine, Oxaliplatin, Retifanlimab
- Where
- 8 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Multiple Myeloma
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
This is an open-label, Phase II, single center trial of pembrolizumab (MK-3475), lenalidomide and dexamethasone in subjects with high risk Multiple Myeloma (hrMM) post high-dose chemotherapy with autologous stem cell…
- Trial name
- NCT02906332
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hackensack Meridian Health
Locally Advanced Unresectable Pancreatic Adenocarcinoma
STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Trial name
- CA209-9KH (NCT04098432)
- Testing
- Nivolumab, Stereotactic radiotherapy
- Where
- 4 sites in Czechia
- Volunteers
- 15 people
- Sponsor
- University Hospital Hradec Kralove
Oral Squamous Cell Carcinoma (OSCC)
Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma
This is a Phase II, single-centre, non-randomized, single-arm clinical trial to investigate the efficacy and safety of neoadjuvant nivolumab therapy in adult participants with resectable, locoregionally advanced Oral Squamous…
- Trial name
- NOCANO (NCT07514767)
- Testing
- Nivolumab (240 mg)
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Prof. Lars Olaf Cardell
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Hepatocellular Carcinoma
PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7
This is a retrospective study that retrospectively included patients with intermediate and advanced HCC beyond up to seven who received first-line treatment with PD-1/PD-L1 inhibitors and anti-angiogenic agents combined…
- Trial name
- NCT06423144
- Testing
- TACE/HAIC, PD-1/PD-L1 inhibits and anti-angiogenic agents
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.